GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Days Sales Outstanding

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Days Sales Outstanding : 110.04 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Days Sales Outstanding?

Chugai Pharmaceutical Co's average Accounts Receivable for the three months ended in Mar. 2024 was $1,907 Mil. Chugai Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was $1,582 Mil. Hence, Chugai Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 110.04.

The historical rank and industry rank for Chugai Pharmaceutical Co's Days Sales Outstanding or its related term are showing as below:

CHGCF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 96.07   Med: 115.24   Max: 136.53
Current: 107.84

During the past 13 years, Chugai Pharmaceutical Co's highest Days Sales Outstanding was 136.53. The lowest was 96.07. And the median was 115.24.

CHGCF's Days Sales Outstanding is ranked worse than
77.82% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs CHGCF: 107.84

Chugai Pharmaceutical Co's Days Sales Outstanding declined from Mar. 2023 (126.95) to Mar. 2024 (110.04).


Chugai Pharmaceutical Co Days Sales Outstanding Historical Data

The historical data trend for Chugai Pharmaceutical Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Days Sales Outstanding Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.75 98.83 115.54 135.22 142.19

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.95 115.52 110.48 104.35 110.04

Competitive Comparison of Chugai Pharmaceutical Co's Days Sales Outstanding

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Days Sales Outstanding falls into.



Chugai Pharmaceutical Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Chugai Pharmaceutical Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (3798.975 + 2214.812) / 2 ) / 7718.818*365
=3006.8935 / 7718.818*365
=142.19

Chugai Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (2214.812 + 1599.728) / 2 ) / 1581.573*365 / 4
=1907.27 / 1581.573*365 / 4
=110.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Chugai Pharmaceutical Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines